本文選題：臨床樣品 + 微流控芯片��； 參考：《色譜》2017年01期

【摘要】：癌癥作為常見病正嚴(yán)重威脅著我國乃至全球居民的健康。循環(huán)腫瘤細(xì)胞(CTCs)是一類由癌變部位釋放并進(jìn)入血液中的癌細(xì)胞,其在癌癥的早期診斷、個(gè)體化及腫瘤轉(zhuǎn)移機(jī)制研究等方面的作用正逐漸被發(fā)現(xiàn)和認(rèn)可,但由于血液中的CTCs含量極少,對(duì)其分選極具挑戰(zhàn)。微流控芯片作為一種微型化、高通量、集成化平臺(tái),在CTCs研究中彰顯了獨(dú)特的優(yōu)勢(shì),相關(guān)報(bào)道也越來越多。隨著研究的深入,微流控芯片技術(shù)不再局限于基于模型樣品的方法學(xué)開發(fā),而是更注重于能否用于臨床實(shí)際樣品中CTCs的檢測(cè),但目前未見該角度的綜述報(bào)道。為此,文章綜述了近年來用于臨床實(shí)際樣品CTCs分析的微流控芯片分選技術(shù),并探討了微流控芯片用于CTCs分選的發(fā)展趨勢(shì)。
[Abstract]:As a common disease, cancer is a serious threat to the health of Chinese and even global residents. Circulating tumor cells (CTCs) are a kind of cancer cells released from cancerous sites and entered the blood. Their roles in the early diagnosis of cancer, individualization and the study of tumor metastasis mechanism are gradually being discovered and recognized. However, because of the very small amount of CTCs in the blood, the separation of CTCs is very challenging. As a miniaturized, high-throughput and integrated platform, microfluidic chip has demonstrated its unique advantages in CTCs research and has been reported more and more. With the deepening of research, microfluidic chip technology is no longer limited to the development of model-based methodology, but more focused on whether it can be used in the detection of CTCs in clinical samples. In this paper, the microfluidic chip sorting technology used for CTCs analysis of clinical samples in recent years is reviewed, and the development trend of microfluidic chips for CTCs sorting is discussed.
【作者單位】： 天津大學(xué)藥物科學(xué)與技術(shù)學(xué)院天津化學(xué)化工協(xié)同創(chuàng)新中心天津市現(xiàn)代藥物傳遞及功能化高效能轉(zhuǎn)化重點(diǎn)實(shí)驗(yàn)室;
【基金】：國家自然科學(xué)基金項(xiàng)目(21375093,21605112) 高等學(xué)校博士學(xué)科點(diǎn)專項(xiàng)科研基金項(xiàng)目(20130032120081) 天津市應(yīng)用基礎(chǔ)與前沿技術(shù)研究計(jì)劃青年項(xiàng)目(15JCQNJC43200)~~
【分類號(hào)】：R730.4
，

本文編號(hào)：2076778